
Aviva Biopharm Reveals Promising Preclinical Results for d3-T, a First-in-Class Women’s Testosterone Therapy, at ENDO 2025
Aviva Biopharm Reveals Promising Preclinical Results for d3-T, a First-in-Class Women’s Testosterone Therapy, at ENDO 2025 Aviva Biopharm Inc. (Aviva Bio), a clinical-stage biopharmaceutical company developing next-generation hormone therapies for women, announced today that new preclinical data on its lead…












